Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention
C Kimmelstiel, P Zhang, NK Kapur… - Circulation …, 2011 - Am Heart Assoc
Background—Bivalirudin, a direct thrombin inhibitor, is a widely used adjunctive therapy in
patients undergoing percutaneous intervention (PCI). Thrombin is a highly potent agonist of …
patients undergoing percutaneous intervention (PCI). Thrombin is a highly potent agonist of …
Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
NE Lepor - Reviews in Cardiovascular Medicine, 2007 - europepmc.org
The anticoagulant properties of heparin were discovered in 1916, and by the 1930s
researchers were evaluating its therapeutic use in clinical trials. Treatment of unstable …
researchers were evaluating its therapeutic use in clinical trials. Treatment of unstable …
Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: Effects on platelet function, thrombelastographic indexes, and their relation to …
Objectives: The primary objective of this study was to compare the effect of therapy with
bivalirudin alone versus bivalirudin plus eptifibatide on platelet reactivity measured by …
bivalirudin alone versus bivalirudin plus eptifibatide on platelet reactivity measured by …
The influence of direct thrombin inhibitors on the formation of platelet-leukocyte aggregates and tissue factor expression
C Christersson, M Johnell, A Siegbahn - Thrombosis research, 2010 - Elsevier
INTRODUCTION: High concentrations of platelet-monocyte aggregates (PMAs) have been
found in patients with myocardial infarction (MI). Oral direct thrombin inhibitors (DTIs) are …
found in patients with myocardial infarction (MI). Oral direct thrombin inhibitors (DTIs) are …
Bivalirudin for the treatment of heparin-induced thrombocytopenia
JR Bartholomew, J Prats - Heparin-induced thrombocytopenia, 2012 - taylorfrancis.com
INTRODUCTION Bivalirudin (Angiomax), a direct thrombin inhibitor (DTI), has been
approved in 42 countries worldwide. In the United States, Argentina, and Peru it is approved …
approved in 42 countries worldwide. In the United States, Argentina, and Peru it is approved …
Bivalirudin with provisional glycoprotein IIb/IIIa inhibitors in patients undergoing primary angioplasty in the setting of cardiogenic shock
L Bonello, A De Labriolle, P Roy, DH Steinberg… - The American journal of …, 2008 - Elsevier
In patients undergoing percutaneous coronary intervention (PCI), clinical trials have
demonstrated that the use of bivalirudin with provisional glycoprotein IIb/IIIa inhibitors is not …
demonstrated that the use of bivalirudin with provisional glycoprotein IIb/IIIa inhibitors is not …
Comparison of prolonged bivalirudin infusion versus intraprocedural in preventing myocardial damage after percutaneous coronary intervention in patients with …
B Cortese, A Picchi, A Micheli, AG Ebert, F Parri… - The American journal of …, 2009 - Elsevier
Modern antithrombotic strategies for patients undergoing percutaneous coronary
interventions (PCIs) must take into account the risk of ischemic and hemorrhagic …
interventions (PCIs) must take into account the risk of ischemic and hemorrhagic …
Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin
RB Eslam, N Reiter, A Kaider, S Eichinger… - European heart …, 2009 - academic.oup.com
Aims We examined the specific effects of unfractionated heparin and bivalirudin on thrombin-
inducible platelet PAR-1 in patients undergoing percutaneous coronary intervention (PCI) …
inducible platelet PAR-1 in patients undergoing percutaneous coronary intervention (PCI) …
Peptide and protein based pharmaceuticals
G Mezo - 2013 - books.rsc.org
The mainstream of the drug development in the 20th century was based on compounds
obeying the 'rule-of-five'(also known as Lipinski's 'rule-of-five'or Pfizer's 'rule-of-five'), which …
obeying the 'rule-of-five'(also known as Lipinski's 'rule-of-five'or Pfizer's 'rule-of-five'), which …
Streamlining the design of promising clinical trials: in-vitro testing of antithrombotic regimens and multiple agonists of platelet activation
DJ Schneider, BE Sobel - Coronary Artery Disease, 2009 - journals.lww.com
Platelets are activated in vivo by multiple agonists; however, platelet function testing in vitro
has been performed predominantly with only one or two agonists of platelet activation …
has been performed predominantly with only one or two agonists of platelet activation …